The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting.

Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K., Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., Du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO, <<INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER>>, 2011; 21 (2): 289-295. [doi:10.1097/IGC.0b013e31820aaafd] [http://hdl.handle.net/10807/3708]

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

Scambia, Giovanni;Lorusso, Domenica;
2011

Abstract

The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting.
2011
Inglese
Harter, P., Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K., Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., Du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO, <<INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER>>, 2011; 21 (2): 289-295. [doi:10.1097/IGC.0b013e31820aaafd] [http://hdl.handle.net/10807/3708]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/3708
Citazioni
  • ???jsp.display-item.citation.pmc??? 56
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact